Skip to main content

Human LIF Antibody

R&D Systems, part of Bio-Techne | Catalog # AB-250-NA

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AB-250-NA

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Neutralization, Western Blot

Cited:

Neutralization

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

E. coli-derived recombinant human LIF
Ser23-Phe202
Accession # P15018

Specificity

Detects human LIF in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 25% cross-reactivity with recombinant mouse LIF is observed. Neutralizes the biological activity of recombinant human LIF and will also neutralize the biological activity of recombinant mouse LIF at a 50-fold higher IgG concentration.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human LIF Antibody

Cell Proliferation Induced by LIF and Neutralization by Human LIF Antibody.

Cell Proliferation Induced by LIF and Neutralization by Human LIF Antibody.

Recombinant Human LIF (Catalog # 7734-LF) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line) as measured by Resazurin (Catalog # AR002). Proliferation elicited by 0.5 ng/mL Recom-binant Human LIF is neutralized (green line) by increasing concentrations of Goat Anti-Human LIF Polyclonal Antibody (Catalog # AB-250-NA). The ND50 is typically 0.1-0.4 µg/mL.

Applications for Human LIF Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Human LIF

Neutralization

Measured by its ability to neutralize LIF-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND50) is typically 0.1-0.4 µg/mL in the presence of 0.5 ng/mL Recombinant Human LIF.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Reconstitution

Reconstitute at 1 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LIF

LIF (Leukemia inhibitory factor; also  Differentiation-stimulating factor) is a 22 kDa (predicted) glycoprotein, member of  the leukemia inhibitory factor/interleukin-6 (LIF/IL-6) family of cytokines. Natural LIF is heavily glycosylated, showing an apparent molecular weight of 32 kDa to 62 kDa, it is produced by a variety of cells including T cells, monocytes, fibroblasts, osteoblasts and mast cells. LIF induces hematopoietic differentiation in normal and myeloid leukemia cells, neuronal cell differentiation and stimulation of acute-phase protein synthesis in hepatocytes. Human LIF acts through a receptor comprising a 190 kDa LIF-binding alpha-chain and a 130 kDa signal-transducing beta-chain (gp130), which is shared with the other members of the IL-6 family. Human and mouse LIF exhibit 78% aa sequence identity.

Long Name

Leukemia Inhibitory Factor

Alternate Names

D Factor, Emfilermin, HILDA, MLPLI

Entrez Gene IDs

3976 (Human); 16878 (Mouse); 403449 (Canine)

Gene Symbol

LIF

UniProt

Additional LIF Products

Product Documents for Human LIF Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human LIF Antibody

For research use only

Loading...
Loading...
Loading...
Loading...